The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.

For patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and then surgery is promising.

BeiGene (BGNE) announced that the European Commission has approved Tevimbra in combination with chemotherapy for the first-line treatment of ...

Shares of BeiGene rose Wednesday morning after the company said it has received regulatory approval for its treatment of gastric and esophageal cancers from the European Union. Shares were recently up ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

BeiGene ($BGNE) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high ...

(RTTNews) - BeiGene, Ltd. (BGNE), Wednesday said that the European Commission has approved Tevimbra in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma ...

The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

Dr. Harvey Tatum with the Utica Park Clinic joined News On 6 at 4 p.m. to discuss treating GERD, and ways to avoid it.

20, after a short illness. She was 71. According to information provided by her business partner, Jay Sloves, Elkinson-Miller ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...